Airway and Systemic Immune Responses Following the Third COVID-19 Vaccination in COPD Patients

References

• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–1302. doi:10.1016/S1473-3099(22)00320-6
   PubMed Web of Science ®Google Scholar
• Gross R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine. 2022;75:103761. doi:10.1016/j.ebiom.2021.103761
   PubMed Web of Science ®Google Scholar
• Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, Phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131–1141. doi:10.1016/S1473-3099(22)00271-7
   PubMed Web of Science ®Google Scholar
• Kherabi Y, Launay O, Luong Nguyen LB. COVID-19 vaccines against omicron variant: real-world data on effectiveness. Viruses. 2022;14(10):2086. doi:10.3390/v14102086
   PubMed Web of Science ®Google Scholar
• Shao W, Chen X, Zheng C, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis. Emerg Microbes Infect. 2022;11(1):2383–2392. doi:10.1080/22221751.2022.2122582
   PubMed Web of Science ®Google Scholar
• Singh D, Mathioudakis AG, Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. Curr Opin Pulm Med. 2022;28(2):76–83. doi:10.1097/MCP.0000000000000834
   PubMed Web of Science ®Google Scholar
• Parpaleix A, Boyer L, Wiedemann A, et al. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J Allergy Clin Immunol. 2017;140(6):1754–1757 e6. doi:10.1016/j.jaci.2017.07.038
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Dossena F, Gnemmi I, et al. Decreased humoral immune response in the bronchi of rapid decliners with chronic obstructive pulmonary disease. Respir Res. 2022;23(1):200. doi:10.1186/s12931-022-02125-3
   PubMed Web of Science ®Google Scholar
• Zwaans WA, Mallia P, van Winden MEC, et al. The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease—a systematic review. J Clin Virol. 2014;61(2):181–188. doi:10.1016/j.jcv.2014.06.025
   PubMed Web of Science ®Google Scholar
• Southworth T, Jackson N, Singh D. Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects. Eur Respir J. 2022;60(2):2200497. doi:10.1183/13993003.00497-2022
   PubMed Web of Science ®Google Scholar
• Zamorano Cuervo N, Grandvaux N. ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Elife. 2020;9. doi:10.7554/eLife.61390
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi:10.1016/S0140-6736(20)31604-4
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920–1931. doi:10.1056/NEJMoa2022483
   PubMed Web of Science ®Google Scholar
• Farahat RA, Abdelaal A, Umar TP, et al. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends. Infez Med. 2022;30(4):480–494. doi:10.53854/liim-3004-2
   PubMedGoogle Scholar
• D’Arminio N, Giordano D, Scafuri B, et al. In silico analysis of the effects of omicron spike amino acid changes on the interactions with human proteins. Molecules. 2022;27(15):4827. doi:10.3390/molecules27154827
   PubMed Web of Science ®Google Scholar
• Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–1312. doi:10.1016/S0140-6736(22)00462-7
   PubMed Web of Science ®Google Scholar
• Agusti A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023
   PubMed Web of Science ®Google Scholar
• Chaiwong W, Takheaw N, Laopajon W, et al. Neutralizing antibody and T-cell responses against SARS-CoV-2 wild-type and variants of concern in chronic obstructive pulmonary disease subjects after ChAdOx-1/ChAdOx-1 homologous vaccination: a preliminary study. Vaccines. 2022;10(12):2176. doi:10.3390/vaccines10122176
   Web of Science ®Google Scholar
• Havervall S, Marking U, Svensson J, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N Engl J Med. 2022;387(14):1333–1336. doi:10.1056/NEJMc2209651
   PubMed Web of Science ®Google Scholar
• Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022;14(2):187. doi:10.3390/v14020187
   PubMed Web of Science ®Google Scholar
• Marking U, Bladh O, Havervall S, et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-a responses and protection. Lancet Infect Dis. 2023;23(2):150–152. doi:10.1016/S1473-3099(22)00834-9
   PubMed Web of Science ®Google Scholar
• Bladh O, Marking U, Havervall S, et al. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose. Lancet Microbe. 2023;4(7):e488. doi:10.1016/S2666-5247(23)00102-7
   PubMedGoogle Scholar
• Tut G, Lancaster T, Krutikov M, et al. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes. Nat Aging. 2023;3(1):93–104. doi:10.1038/s43587-022-00328-3
   PubMedGoogle Scholar
• Ozbay Kurt FG, Lepper A, Gerhards C, et al. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. Front Immunol. 2022;13:1012526. doi:10.3389/fimmu.2022.1012526
   PubMed Web of Science ®Google Scholar
• Forgacs D, Silva-Moraes V, Sautto GA, et al. The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination. Vaccines. 2022;10(5):696. doi:10.3390/vaccines10050696
   Web of Science ®Google Scholar
• Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022;379:e072141. doi:10.1136/bmj-2022-072141
   PubMedGoogle Scholar
• Terreri S, Piano Mortari E, Vinci MR, et al. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host Microbe. 2022;30(3):400–408 e4. doi:10.1016/j.chom.2022.01.003
   PubMed Web of Science ®Google Scholar
• Muecksch F, Wang Z, Cho A, et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607(7917):128–134. doi:10.1038/s41586-022-04778-y
   PubMed Web of Science ®Google Scholar
• Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263–2264. doi:10.1016/S0140-6736(22)00941-2
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang R, Qiao S, et al. Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. N Engl J Med. 2022;387(3):277–280. doi:10.1056/NEJMc2206900
   PubMed Web of Science ®Google Scholar
• Nadesalingam A, Cantoni D, Aguinam ET, et al. Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies. Lancet Microbe. 2023;4(2):e58–e59. doi:10.1016/S2666-5247(22)00297-X
   PubMedGoogle Scholar
• Rosenblum HG, Wallace M, Godfrey M, et al. Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines — United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022;71(45):1436–1441. doi:10.15585/mmwr.mm7145a2
   PubMed Web of Science ®Google Scholar
• Lee IT, Cosgrove CA, Moore P, et al. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. Lancet Infect Dis. 2023;23(9):1007–1019. doi:10.1016/S1473-3099(23)00295-5
   PubMed Web of Science ®Google Scholar
• Aksyuk AA, Bansal H, Wilkins D, et al. AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. Cell Rep Med. 2023;4(1):100882. doi:10.1016/j.xcrm.2022.100882
   PubMedGoogle Scholar
• Liew F, Talwar S, Cross A, et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2023;87:104402. doi:10.1016/j.ebiom.2022.104402
   PubMed Web of Science ®Google Scholar
• Curlin ME, Bates TA, Guzman G, et al. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection. Med. 2022;3(12):827–837 e3. doi:10.1016/j.medj.2022.09.001
   PubMedGoogle Scholar
• Naaber P, Tserel L, Kangro K, et al. Protective antibodies and T cell responses to omicron variant after the booster dose of BNT162b2 vaccine. Cell Rep Med. 2022;3(8):100716. doi:10.1016/j.xcrm.2022.100716
   PubMedGoogle Scholar